

# What effect does testosterone gel have on female steroid levels?

<b>Submission date</b> 09/01/2019	<b>Recruitment status</b> No longer recruiting	<input checked="" type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
<b>Registration date</b> 11/01/2019	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
<b>Last Edited</b> 31/03/2025	<b>Condition category</b> Nutritional, Metabolic, Endocrine	<input type="checkbox"/> Individual participant data

## Plain English summary of protocol

### Background and study aims

In the context of sport, steroids, principally testosterone, are the most used drugs for doping. However, since it is also a molecule produced by our own body, its detection is challenging and therefore requires new detection method development. In addition, the off-label use of clinical testosterone in women is increasing for the treatment of low libido. However, there is little information on the woman's metabolism response resulting from testosterone administration. This study should allow us to know to what extent the administration of transdermal testosterone influences the steroidal profile (blood and urine) of the healthy woman. Indeed, this route of administration is recognized to be the most frequently used for doping purposes.

### Who can participate?

Healthy women, aged between 20 and 40 years, and not using hormonal contraception will be recruited for this study.

### What does the study involve?

The study is an open-label trial, in which all participants will receive the same treatment. The study takes place over a period of 12 weeks divided into three main phases. Each phase corresponds to a menstrual cycle. The first phase is a follow-up phase during which no treatment is administered but with regular blood and urine collections to establish a baseline. It corresponds to the control phase. The second phase is that of intervention during which a testosterone gel (Tostran) will be applied daily (28 days) on the skin (abdomen and inner thighs) of the volunteers. The daily dose will be 0.5 g of gel corresponding to 10 mg of testosterone administered. Tostran is a testosterone gel approved and marketed in Switzerland. It is used in the substitution treatment of testosterone in adult men during various health problems caused by a deficiency of testosterone (male hypogonadism). The blood and urine samples are collected as in phase I. This phase is followed by phase III, called post-treatment, which is similar to phase I. No intervention is administered and only urine and blood samples are collected.

### What are the possible benefits and risks of participating?

Participation in the study is a help for the fight against doping and for the improvement of female metabolism comprehension. The most frequently reported side effects linked to Tostran administration are local skin reactions due to the presence of butylhydroxytoluene (E321) in the

drug. It also happens that a long-term treatment causes swelling of the hands and / or feet, hair loss, hypertension, increased body hair, impaired biological balance, cutaneous hypersensitivity, acne , and oily skin.

Since the doses administered will be 6 times lower than those recommended for substitution treatment in humans, these adverse effects will be limited.

Where is the study run from?

This pilot study is conducted only in Switzerland, in Lausanne at the Centre Hospitalier Universitaire Vaudois (CHUV).

When is the study starting and how long is it expected to run for?

The study is supposed to start 01/03/2019 and will last approximately until 31/10/2019.

Who is funding the study?

The World Anti-Doping Agency (WADA).

Who is the main contact?

Martial Saugy

martial.saugy@unil.ch

## Contact information

### Type(s)

Public

### Contact name

Mr Olivier Salamin

### ORCID ID

<https://orcid.org/0000-0003-0388-1352>

### Contact details

ISSUL - Institut des Sciences du Sports

Synthlone - Quartier Centre

Lausanne

Switzerland

1015

### Type(s)

Scientific

### Contact name

Prof Martial Saugy

### Contact details

ISSUL - Institut des Sciences du Sports

Synthlone - Quartier Centre

Lausanne

Switzerland

1015

# Additional identifiers

## Protocol serial number

2018-02106

# Study information

## Scientific Title

Establishment of the female steroid profile and impact of transdermal testosterone administration on the steroidal metabolism: open-label trial

## Acronym

TestoFem

## Study objectives

Transdermal testosterone administration influences the female steroid metabolism.

## Ethics approval required

Old ethics approval format

## Ethics approval(s)

Approved 04/06/2019, Canton de Vaud Human Research Ethics Commission (Av de Chailly 23, 1012 Lausanne, Switzerland; +41 213161830; Secretariat.CER@vd.ch), ref: 2018-02106

## Study design

Single-centre open-label trial

## Primary study design

Interventional

## Study type(s)

Other

## Health condition(s) or problem(s) studied

Steroid metabolism

## Interventions

The trial is an open-label trial which means that every participant will receive the treatment and will know what is the treatment. A treatment with testosterone gel will be administered for 28 days. The product used for the study is Tostran 20 mg/g and 0.5 g of the product corresponding to 10 mg of testosterone will be applied daily on the skin of participants.

## Intervention Type

Drug

## Phase

Not Applicable

## Drug/device/biological/vaccine name(s)

Tostran (testosterone gel)

### **Primary outcome(s)**

Serum testosterone concentration will be measured using UHPLC-MS/MS during the whole study.

### **Key secondary outcome(s)**

1. Urinary and serum steroid profile with GC-MS and UHPLC-MS/MS before, during and after treatment.
2. Untargeted metabolomics study with UHPLC-HRMS for discovery of potential biomarkers of testosterone abuse with comparison of metabolic profile before, during and after treatment.
3. Analyses of urine samples with IRMS during the treatment phase.
4. Body composition measurement with DEXA scan before and after treatment.
5. Hematological profile with Sysmex XN-1000 during the whole study.
6. Endocrinological profile (LH, FSH, hCG, SHBG) during the whole study measured with clinical chemistry.
7. Self-esteem and quality of life using specific questionnaires (Rosenberg self-esteem scale and SF-96 questionnaire) before and after treatment.

### **Completion date**

06/08/2020

## **Eligibility**

### **Key inclusion criteria**

1. Female
2. Aged 20-40 years old
3. Body mass index between 18 and 30 kg/m<sup>2</sup>
4. Hemoglobin concentration between 12 and 16 g/dL
5. Negative pregnancy test at screening
6. Basal testosterone concentration  $\leq 1.5$  nmol/L
7. Regular menstrual cycles (26-32 days)
8. Normal biological balance (complete blood count, liver function (ASAT / ALAT), CRP, renal function (creatinine))
9. Normal hormone balance (LH, FSH, SHBG, cortisol, prolactin)

### **Participant type(s)**

Healthy volunteer

### **Healthy volunteers allowed**

No

### **Age group**

Adult

### **Lower age limit**

18 years

### **Sex**

Female

**Total final enrolment**

14

**Key exclusion criteria**

1. Hypertension (SBP> 140 and DBP> 90 mmHg)
2. Regular intake of tobacco (max 1 cigarette / day) or alcohol (max 1 drink / week)
3. Regular intake of anabolic or ergogenic drugs
4. Holder of a license in a sports discipline
5. Current acne or hirsutism deemed clinically significant
6. Dyslipidemia or hypercholesterolemia
7. Hyperprolactinaemia
8. Endocrine or metabolic disease
9. Tumor of pituitary gland or hypothalamus
10. Contraindications to the class of the substance administered (hypersensitivity or allergy to the active substance or to any of the excipients)
11. Treatment with synthetic anti-thyroid or thyroid hormones
12. Treatment with ketoconazole, anticoagulants, ACTH, corticosteroids
13. Cardiovascular, hepatic, renal or biliary disease
14. Current use of hormonal contraceptives or during the two months preceding the study
15. Pregnancy present or envisaged within 6 months after the end of the study
16. Breastfeeding
17. Eating disorders
18. Previous participation in another study in the last 30 days
19. Sports competition scheduled within 9 months after the end of the study
20. Donation of blood during the last 3 months
21. Migraine
22. Neoplasia or history of neoplasia

**Date of first enrolment**

01/03/2019

**Date of final enrolment**

31/03/2020

**Locations****Countries of recruitment**

Switzerland

**Study participating centre**

**Centre de recherche clinique de la Faculté de biologie et médecine et du CHUV**

Rue du Bugnon 44

Lausanne

Switzerland

1011

**Study participating centre**

**Service d'endocrinologie, diabétologie et métabolisme du CHUV**  
Avenue de la Sallaz 8  
Lausanne  
Switzerland  
1011

## Sponsor information

### Organisation

Research and Expertise in antiDoping sciences - Université de Lausanne

### ROR

<https://ror.org/019whta54>

## Funder(s)

### Funder type

Other

### Funder Name

World Anti-Doping Agency

### Alternative Name(s)

l'Agence mondiale antidopage, wada\_ama, AMA, WADA

### Funding Body Type

Private sector organisation

### Funding Body Subtype

Other non-profit organizations

### Location

Canada

## Results and Publications

### Individual participant data (IPD) sharing plan

The datasets generated and/or analysed during the current study during this study will be included in the subsequent results publication.

### IPD sharing plan summary

Other

## Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Results article</a>			11/05/2021	Yes	No
<a href="#">Results article</a>		29/03/2025	31/03/2025	Yes	No
<a href="#">Participant information sheet</a>	Participant information sheet	11/11/2025	11/11/2025	No	Yes